Amgen Signs a Research Agreement with the University of Washington’s IPD for the Development of Protein-Based Therapies

Amgen Signs a Research Agreement with University of Washington's IPD for the Development of Protein-Based Therapies

Shots:

  • The Institute for Protein Design will utilize its de novo design technique to expand the versatility of protein-based therapies. Amgen has provided funding for three research projects utilizing IPD’s de novo design technique & optimizing Amgen’s repertoire of BiTE Ab
  • The focus of the collaboration is to test new technologies & develop protein-based therapies with the goal of expanding the types of tumors targeted by the therapies
  • IPD helps Amgen to develop Ab against drug targets and to produce new ways, modulating the activity of the immune system. BiTE (Bispecific T cell engager) technology is an immune-oncology platform, engaging patients’ own T cells to tumor-specific antigen, eliminating detectable cancer

Click here to read full press release/ article | Ref: Amgen | Image: Pinterest